Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oklahoma state attorney general is suing company for $17bn, to fund treatment and offset other costs of the opioid epidemic

Johnson & Johnson ran 'cunning' scheme to market opioids, attorney says

On Tuesday, July 16, Johnson & Johnson (NYSE: JNJ) will release its latest earnings report.

Johnson & Johnson Q2 Earnings Outlook

Johnson & Johnson (NYSE: JNJ) is scheduled to report its most recent quarterly results before the markets open on Tuesday.

What to Watch When Johnson & Johnson Reports Tomorrow

Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis.

Oklahoma at trial's end says opioid 'kingpin' J&J fueled epidemic

Lawyers for the state of Oklahoma on Monday urged a judge to hold Johnson & Johnson responsible for fueling the U.S. opioid epidemic, as the first trial nationally in litigation over the drug crisis came to an end.

Oklahoma urges judge to hold J&J responsible for opioid crisis as trial ends

Ford Motor Company

Block

Options trading was buzzing in Square, Ford, and Johnson & Johnson on Friday. Here are the metrics that matter moving forward.

Monday’s Vital Data: Johnson & Johnson, Ford and Square

JNJ stock is facing multiple negative catalysts, including lawsuits and regulatory risk. Investors should avoid Johnson & Johnson stock.

Johnson & Johnson Stock Facing Negative Catalysts Ahead of Q2 Results

The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.

J&J Falls Amid Reports of Criminal Probe Into Talcum Powder

eBay

Microsoft

Netflix

Honeywell

Schlumberger

United Continental Hlds

UnitedHealth Group

Now that the second-quarter earnings reporting season is just kicking off, many major companies will be sharing their results in the coming weeks.

Microsoft, Netflix, eBay, Johnson & Johnson and More Major Earnings Coming This Week

The healthcare giant is reportedly under investigation by the Department of Justice.

Here's Why Johnson & Johnson Dropped 4% Today

Aurora Cannabis

Illumina

Square, Johnson & Johnson, Illumina, Canopy Growth and Aurora Cannabis are our top stock trades for Monday.

4 Top Stock Trades for Monday: JNJ, SQ, ILMN, ACB

Abbott Labs

Intuitive Surgical

These healthcare stocks are breaking down on the charts. Investors should be careful before stepping into these four.

4 Healthcare Stocks That Are Feeling Sick  

Johnson & Johnson (JNJ) stock fell over 4% Friday as the company is being investigated over potentially lying about its talc causing cancer.
The post Johnson & Johnson Baby Powder News: JNJ Stock Drops on Investigation appeared first on InvestorPlace.

Johnson & Johnson Baby Powder News: JNJ Stock Drops on Investigation

Shares of Johnson & Johnson (NYSE: JNJ) were trading lower Friday after Bloomberg reported that the Justice Department has launched a criminal probe into the company.

Johnson & Johnson Falls On Report Of Justice Department Probe

The U.S. Justice Department is pursuing a criminal probe into whether Johnson & Johnson lied about potential cancer risks of its talcum powder and has convened a grand jury in Washington, Bloomberg reported on Friday, citing people with knowledge of the matter.

J&J faces U.S. criminal probe related to baby powder: Bloomberg

Shares of Johnson & Johnson JNJ, -4.49% fell 4.3% in Friday afternoon trade after Bloomberg reported that the U.S.

Johnson & Johnson stock dives 4.3% after Bloomberg reports that DOJ is pursuing criminal investigation into company

Johnson & Johnson will conduct a study for it later this year.

HIV vaccine to begin testing internationally

The US Justice Department is pursuing a criminal probe into whether Johnson & Johnson lied about potential cancer risks of its talcum powder, Bloomberg reported, citing people with knowledge of the matter. A grand jury in Washington is looking into documents related to what company officials knew about any carcinogens in their products, according to.

Johnson & Johnson’s stock tumbles after reports of criminal probe

Johnson & Johnson tumbled Friday on reports the Department of Justice is seeking a criminal investigation into allegations the company lied about potential cancer risks of its talc powders.
The post J&J Stock Dives As DOJ Reportedly Seeks Criminal Probe Into Talc Powders appeared first on Investor's Business Daily.

J&J Stock Dives As DOJ Reportedly Seeks Criminal Probe Into Talc Powders

The Justice Department is pursuing a criminal probe into whether Johnson & Johnson lied about the possible cancer risks of its talcum powder, according to a Bloomberg report.

J&J drops 4% on report DOJ investigating allegations company lied about talc cancer risks

Pharmaceutical giant Johnson & Johnson is set to test an experimental HIV vaccine in the U.S. and Europe sometime this year, the company confirmed with CNBC.

Johnson & Johnson to test HIV vaccine in US and Europe

J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.

J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?

An appeals court has ruled that a new trial is in order for Johnson & Johnson (NYSE: JNJ) after a jury ordered the company to pay $417 million to a woman who claims the company’s baby powder caused cancer, according to Bloomberg.

Johnson & Johnson Wins New Trial In Talc Case

Amgen

Eli Lilly

Medtronic

Merck

Novartis

Pfizer

Thermo Fisher Scientific

How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

The 10 Biggest Healthcare Stocks

Bayer AG

Bayer's (BAYRY) Xarelto, in the phase III EINSTEIN-Jr study in pediatric patients, shows a similar low risk of VTE or blood clots compared to current standard anticoagulation therapy.

News for Johnson & Johnson Stock (JNJ)